Revenue dropped 79% and net profit turned to a loss in Q1 2025, mainly due to weak sales and higher costs. Cash flow improved, and the company is integrating a new biopharma acquisition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.